LifeStance Health Group, Inc. 8-K

What Happened

• LifeStance Health Group, Inc. (LFST) entered into an Underwriting Agreement (dated Feb 25, 2026) with J.P. Morgan Securities LLC and certain selling stockholders for an underwritten offering of 25,000,000 shares of common stock under the company’s Form S-3 registration (File No. 333-279585). The offering closed on March 2, 2026.
• All 25,000,000 shares were sold by the selling stockholders (a secondary offering). The company agreed to purchase 7,000,000 of those shares from the underwriter at the same price the underwriter paid the selling stockholders. The company did not receive any proceeds from the offering. Ropes & Gray LLP issued a legal opinion filed as Exhibit 5.1.

Key Details

• Offering size: 25,000,000 shares of common stock.
• Company repurchase: 7,000,000 shares purchased by the company from the underwriter.
• Dates: Underwriting Agreement dated Feb 25, 2026; offering closed March 2, 2026; Form S-3 registration filed May 21, 2024 (File No. 333-279585).
• Proceeds: All cash proceeds went to the selling stockholders; the company received no proceeds. The filing does not state whether the repurchased shares will be cancelled or held as treasury.

Why It Matters

• This was a secondary offering by existing holders, not a capital raise for the company, so LifeStance did not receive cash from the transaction. That means no direct boost to the company’s balance sheet from this offering.
• The company’s purchase of 7,000,000 shares could affect outstanding share count or treasury holdings depending on whether those shares are cancelled or held, but the filing does not specify the treatment. Investors should monitor follow-up disclosures (e.g., amendment or proxy filings) for details on how the repurchased shares will be accounted for and any impact on share float or ownership.